Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
255
resultados
Última actualización
26/06/2026 [06:53:00]
Resumen de: US20260174733A1
A proliposomal delivery system and method for preparing the same is provided. The proliposomal delivery system involves a proliposomal formulation incorporating liposomal entrapment of vitamin C within a nano-emulsion that is stabilized using partially hydrolyzed guar gum. The proliposomal formulation includes ascorbic acid as the active ingredient, sunflower lecithin with a phosphatidylcholine content as an encapsulating material, and partially hydrolyzed guar gum as a dietary polysaccharide. The proliposomal formulation is a safer and more bioavailable form of vitamin C designed to minimize gastric discomfort. The proliposomal formulation offers a nutraceutical supplement aimed at managing oxidative stress, enhancing immune system function, supporting heart health, and improving skin. The process provided for preparing the proliposomal formulation is simple, cost-effective and scalable.
Resumen de: US20260174820A1
The present invention provides an ionizable polymer comprising a constitutional unit according to formula (I). wherein R1 and R2 are as defined in the specification. The ionizable polymer of the invention finds use in the intracellular delivery of polynucleotides in vitro and in vivo. The present invention also provides compositions comprising the ionizable polymer of the invention and a polynucleotide. The compositions disclosed herein find utility as medicaments, in particular as medicaments for the prevention or treatment of an infectious disease, a cancer, or a protein-deficiency disease.
Resumen de: AU2024398058A1
The present disclosure describes improved LNP-based RNA vaccines, nucleobase editing systems, and therapeutics for use in treating and/or immunization against disease. In particular, the disclosure describes improved LNPs, including novel and improved ionizable lipids for making LNPs, that enhance the targeted delivery of LNP-based RNA vaccines and therapeutics based on linear and/or circular mRNAs. The improved LNPs protect linear and/or circular mRNA payloads from degradation and clearance while achieving targeted systemic or local delivery for use as enhanced vaccines and/or therapeutic agents.
Resumen de: AU2026204376A1
Antibodies and antigen binding fragments thereof that specifically recognize and bind an epitope of elastin that is exposed and accessible in degraded elastic fiber are described. The antibodies and/or antigen binding fragments can be operably linked to a secondary component, including biologically active agents such as therapeutics and/or imaging agents. Optionally, the antibodies and/or antigen binding fragments thereof can be attached to a surface of a carrier, such as a particle, for specific binding and delivery of the carried agents to degraded elastic fiber. fiber. un u n
Resumen de: US20260174700A1
The invention relates to formulation for oral delivery of peptides and/or drug molecules and a method of manufacturing the same. The oral formulation is useful for delivering peptides to the gastrointestinal tract, preferably at the ileo-caecal junction of colon.
Resumen de: AU2026204465A1
COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES The present invention relates to the treatment of ocular diseases in a human subject. In particular, the invention relates to an intracameral administration of a sustained release biodegradable intracameral implant.5 COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES un u n
Resumen de: AU2024388909A1
The present invention relates to the technical field of medicine, and relates in particular to a molecule having a targeting function. The molecule having a targeting function can specifically deliver a drug to a specific cell, which facilitates precise programming of a specific cell in the body, a therapeutic effect of the drug is produced, and consequently drug dosage and side effects are greatly reduced, and the effect of precise treatment to cells in the body is achieved.
Resumen de: EP4763189A1
The present invention relates to a composition comprising a solid carrier, a lipase or a fragment thereof immobilized on the surface of the solid carrier wherein the lipase or a fragment thereof is in the open conformation, a protease or a fragment thereof immobilized on the surface of the solid carrier, an amylase or a fragment thereof immobilized on the surface of the solid carrier, an agent which interacts with the lid domain of the lipase or a fragment thereof, a protective layer to protect the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof by embedding the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof, and a functional constituent immobilized on the surface of the protective layer, wherein the functional constituent immobilized on the surface of the protective layer is a polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group; b) an amino acid; c) a non-reducing sugar and/or a non-reducing sugar alcohol; and d) a surfactant. The present invention also relates to solid, lyophilized and liquid compositions of said nanoparticle composition, capsules comprising said nanoparticle composition, methods of producing said nanoparticle composition and uses thereof.
Resumen de: EP4763197A1
The present invention relates to a composition comprising a solid carrier, a protein ATP-hydrolyzing enzyme or a fragment thereof immobilized on the surface of the solid carrier, a protective layer to protect the protein ATP-hydrolyzing enzyme or a fragment thereof by embedding the protein ATP-hydrolyzing enzyme or a fragment thereof, and a functional constituent immobilized on the surface of the protective layer, wherein the functional constituent immobilized on the surface of the protective layer is a polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group. The present invention also relates to methods of producing said composition and uses of the composition for the prevention, delay of progression or treatment of dysbiosis or a dysbiosis-related disease. The present invention also relates to a pharmaceutical combination comprising (i) said composition; and (ii) an immune checkpoint modulator and uses thereof for the prevention, delay of progression or treatment of cancer and/or for use in adoptive (T) cell therapy.
Resumen de: EP4763227A1
The present invention relates to a composition comprising a solid carrier, a protein branched-chain amino acid-degrading enzyme or a fragment thereof immobilized on the surface of the solid carrier, a protective layer to protect the protein branched-chain amino acid-degrading enzyme or a fragment thereof by embedding the protein branched-chain amino acid-degrading enzyme or a fragment thereof, and a functional constituent immobilized on the surface of the protective layer, wherein the functional constituent immobilized on the surface of the protective layer is a polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group. The present invention also relates to methods of producing said composition and uses of the composition for the prevention, delay of progression or treatment of branched-chain amino acid metabolism related diseases.
Resumen de: WO2025038864A1
The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use, including compounds of Formula (I) or a pharmaceutically acceptable salt thereof.
Resumen de: EP4763287A2
The invention relates to novel polymer conjugated lipids and to novel compositions comprising said novel polymer conjugated lipids useful for the delivery of nucleic acids into living cells.
Resumen de: WO2025040887A1
Described is a nanopore that is selectively convertible between an open form and a closed form using light, a method for producing such a nanopore, a method of modulating the flow of one or more substances through the nanopore, the use of the nanopore in modulating ionic flow across an amphiphilic membrane, a device comprising the nanopore, use of the nanopore as an ionotronic component, use of the nanopore in bio-computation and/or bioionotronics, a method of transmitting information using the nanopore, and method of receiving information comprising the nanopore, and an ionotronic component comprising the nanopore.
Resumen de: WO2025036956A1
The present invention relates to compositions designed for localized delivery within a subject's body. More particularly, the invention pertains to therapeutic compositions that remain localized to specific organs or tissues and do not exhibit systemic distribution. These compositions include specific carriers and therapeutic agents suitable for various medical applications.
Resumen de: WO2025036861A1
The present invention relates to drug delivery, more specifically, to polymersomes used as a drug delivery systems. The present invention also relates to polymersomes comprising a composition for use in treating, for example, ocular disorders and pulmonary disorders.
Resumen de: WO2025062064A1
The present disclosure provides a structural protein comprising an amino acid sequence unit comprising a motif (VPGVG)n, wherein n is 2 or more, and an amino acid sequence selected from SEQ ID NO:1–10. The present disclosure also provides a polynucleotide, an expression vector and a host cell, as well as a method for producing the structural protein. The present disclosure also provides a medical product, an electrospun filament comprising the structural protein, a protein-based micro-robot, photonic crystals, metamaterial and thermoresponsive glass comprising one or more of the structural proteins. The present disclosure also provides a method for preparing a product. The present disclosure also provides use of one or more of the structural proteins for preparing a product.
Resumen de: CN122251335A
本发明涉及一种o/w乳液，其包括油相、水相和分散在水相中的颗粒，其中，所述的颗粒是含有核酸成分的脂质纳米颗粒（LNP），所述颗粒能够稳定油水界面。本发明还公开了一种含该o/w乳液的药物组合物，例如疫苗。
Resumen de: WO2025062315A2
This disclosure relates to methods of manufacturing cardanols and/or derivatives thereof, cardols and/or derivatives thereof, lipids and/or derivatives thereof, and lipid nanoparticles and/or derivatives thereof. The disclosure extends to the cardanols and/or derivatives thereof, the cardols and/or derivatives thereof, the lipids and/or derivatives thereof, and the lipid nanoparticles and/or derivatives thereof. The disclosure further extends to use of lipids, preferably ionizable lipids, in the manufacture of lipid nanoparticles, wherein said lipid nanoparticles are employed in the manufacture of delivery means for active pharmaceutical ingredients (API).
Resumen de: CN122251578A
本发明属于医药材料领域，具体涉及一种金属核增强双势垒压电纳米系统及其制备方法与应用。所述制备方法包括：先通过分步反应制备“金属@介孔二氧化钛@介孔钛酸钡”核壳结构，再经脂质包裹得到目标纳米颗粒。该系统创新的构建了双势垒结构，可在4mmHg生理压力下自触发产生活性氧，实现恶性腹水的内源性压力自驱动治疗，兼具低压高催化效率、长期结构稳定及良好生物相容性优势，解决了现有治疗手段侵入性强、依赖外源刺激的问题，为恶性腹水治疗提供了新型安全高效的技术方案。
Resumen de: CN122251433A
本发明公开一种增强奥沙利铂临床疗效的复合纳米酶及其制备方法和应用，复合纳米酶由铟钌纳米酶和伊利司莫包埋锚定层组成；铟钌纳米酶由铟钌纳米颗粒和碳氮骨架组成，铟钌纳米颗粒负载在碳氮骨架表面和碳氮骨架孔道中；伊利司莫包埋锚定层由双巯基聚乙二醇包覆层和伊利司莫组成。制备方法：将锌盐甲醇溶液和2‑甲基咪唑甲醇溶液共沉淀制备ZIF‑8，焙烧得碳氮骨架；将碳氮骨架分散液与硝酸铟溶液和三氯化钌溶液油浴搅拌制备纳米酶前驱体，焙烧得铟钌纳米酶；将铟钌纳米酶分散至双巯基聚乙二醇溶液中并滴加伊利司莫溶液，将得到的固体产物干燥即得。本发明可以解决奥沙利铂治疗中药物耐受性强、胞内积聚不足以及肿瘤免疫抑制严重等问题。
Resumen de: CN122255146A
本发明公开了一种D–A–D型有机小分子、包含其的纳米颗粒及它们的制备方法与应用。所述D–A–D型有机小分子及其纳米颗粒，特别适用于白血病、淋巴瘤、多发性骨髓瘤等血液系统恶性肿瘤的精准光热治疗与实时成像引导。所述D–A–D型有机小分子，构建了D–A–D型共轭结构，通过增强分子内电荷转移（ICT）效应，实现近红外吸收红移至685nm，并利用高激发态重组能（λ=1.29eV）促进非辐射跃迁，光热转换效率超过35%。该小分子不含金属与卤素，分子量约878Da，具备良好生物相容性与代谢潜力。通过自组装形成粒径约130nm的纳米颗粒，具备良好胶体稳定性与被动靶向能力。同时，其高摩尔吸光系数与高效光热转换特性赋予其强光声成像能力，可实时监测药物分布，实现“诊疗一体化”。
Resumen de: CN122251565A
本发明涉及mRNA疫苗技术领域，具体为多抗原串联mRNA肺癌疫苗及其在制备抗肿瘤药物中的应用，包含mRNA分子与包封该mRNA的脂质纳米颗粒，mRNA自5'端至3'端依次为帽结构、5'非翻译区、开放阅读框、3'非翻译区、polyA尾，开放阅读框编码的融合抗原蛋白，依次包含信号肽、肺癌共享突变抗原模块、肿瘤相关抗原模块、MHC‑I定向转运结构域，各抗原片段间通过AAY连接肽连接，脂质纳米颗粒由离子化脂质、胆固醇、辅助磷脂、PEG‑脂质组成。本发明兼顾抗原特异性与覆盖广度，可高效释放抗原表位，提升抗原呈递效率，强效激活特异性抗肿瘤免疫，适配稳定递送体系，在肺癌治疗中具备良好应用前景。
Resumen de: CN122255484A
本发明提供了一种用于奥沙利铂传输的聚赖氨酸纳米材料及其制备方法，涉及生物制药技术领域。本申请的合成方法合成路线明确、可控性强。通过模块化设计，依次制备炔基化透明质酸、叠氮化聚赖氨酸‑维生素E琥珀酸酯及MMP酶敏感肽段连接体，最终采用点击化学高效偶联，产物结构明确、纯度高、批次间重现性好，克服了传统方法偶联效率低、副产物多的问题。制备得到的药物具备主动靶向与双重响应释药能力，透明质酸可特异性识别肿瘤细胞表面高表达的CD44受体，实现主动靶向；MMP酶敏感肽段可在肿瘤微环境中被过度表达的MMP‑9酶切，实现酶响应释药；同时，载体中引入的二硫键结构可在高浓度谷胱甘肽环境中断裂，实现还原响应释药。
Resumen de: CN122251406A
本发明涉及药物制剂与纳米医学领域，尤其涉及一种纳米药物组合物及其联合给药系统和应用。所述纳米药物组合物包含α1‑AR阻断剂和两亲性纳米载体；所述α1‑AR阻断剂包载于由两亲性纳米载体形成的疏水核心中；所述α1‑AR阻断剂选自哌唑嗪、特拉唑嗪、多沙唑嗪中的一种或多种；所述纳米药物组合物的平均粒径为220‑260 nm，聚合物分散指数＜0.3，包封率＞50%。本发明的纳米药物组合物兼具抗肿瘤增殖与免疫微环境重塑双重功能，提升药物在生理介质中的分散稳定性，有效降低体内清除率、延长循环时间，实现药物的高效体内递送。该纳米制剂的制备工艺稳定、可规模化生产。
Nº publicación: CN122251362A 23/06/2026
Solicitante:
兰州理工大学甘肃省标准化研究院
Resumen de: CN122251362A
本发明用于生物医药与功能食品技术领域，公开了基于黑果枸杞多糖微环境释放的肠道免疫调节系统，所述系统包括：用于递送和释放黑果枸杞多糖的微环境响应型递送单元，所述递送单元由黑果枸杞多糖核心和包覆所述核心的响应层构成，所述响应层包含至少一种能够响应肠道靶部位微环境信号的响应性材料，以使所述递送单元在到达肠道靶部位时，能响应所述微环境信号而发生结构变化，从而实现所述黑果枸杞多糖的定位释放。该基于黑果枸杞多糖微环境释放的肠道免疫调节系统，通过由响应性材料构成的“响应层”对黑果枸杞多糖（LBPs）活性核心进行包覆，构建了一个物理屏障，该系统能够有效抵御上消化道恶劣环境对LBPs结构的破坏。
BOPI
Sede Electrónica
